Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMG 319 neoadjuvant phase IIa trial in head and neck squamous cell carcinoma
2014-004388-20Phase 2Terminated
- Sponsor
- Cancer Research UK
- Start
- May 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in head and neck squamous cell carcinoma (HNSCC) comparing AMG 319 with Placebo (2 arms). Primary endpoint: Change in intratumoral CD8+ effector T cells. Started May 2015; status: terminated.
02
Drugs
AMG-319
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on 2014-004388-20.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-004388-20.